ME02085B - Sklerostin vezujuća sredstva - Google Patents

Sklerostin vezujuća sredstva

Info

Publication number
ME02085B
ME02085B MEP-2013-358A MEP35813A ME02085B ME 02085 B ME02085 B ME 02085B ME P35813 A MEP35813 A ME P35813A ME 02085 B ME02085 B ME 02085B
Authority
ME
Montenegro
Prior art keywords
bone
bone loss
disease
sclerostin
loss
Prior art date
Application number
MEP-2013-358A
Other languages
English (en)
French (fr)
Inventor
Christopher Paszty
Kevin Graham
John Latham
Alastair Lawson
David Winkler
Wenyan Shen
Andy Popplewell
Hsieng Sen Lu
Aaron George Winters
Martyn Kim Robinson
Alistair James Henry
Kelly Sue Hoffmann
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36992590&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ME02085(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of ME02085B publication Critical patent/ME02085B/me

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)

Claims (33)

1.    Sklerostin-vezujuće antitelo, koje sadrži sledeće CDR sekvence:CDR-H1: DYNMH (SEQ ID NO:245);CDR-H2: EINPNSGGAGYNQKFKG (SEQ ID NO:246);CDR-H3: LGYDDIYDDWYFDV (SEQ ID NO:247);CDR-L1: RASQDISNYLN (SEQ ID NO:78);CDR-L2: YTSRLLS (SEQ ID NO:79) iCDR-L3: QQGDTLPYT (SEQ ID NO:80).
2.    Sklerostin-vezujuće antitelo prema zahtevu 1, koje sadrži teški lanac, koji uključuje polipeptidnu sekvencu, koja poseduje najmanje 85% identiteta sekvence SEQ ID NO: 378.
3.    Sklerostin-vezujuće antitelo prema zahtevu 1 ili 2, koje sadrži laki lanac, koji uključuje polipeptidnu sekvencu, koja poseduje najmanje 85% identiteta sekvence SEQ ID NO: 376.
4.    Sklerostin-vezujuće antitelo prema ma kom od zahteva 1 do 3, koje sadrži i teški lanac, koji uključuje polipeptidnu sekvencu, koja poseduje najmanje 85% identiteta sekvence SEQ ID NO: 378 i laki lanac, koji uključuje polipeptidnu sekvencu, koja poseduje najmanje 85% identiteta sekvence SEQ ID NO: 376.
5.    Sklerostin-vezujuće antitelo prema ma kom od zahteva 1 do 4, koje sadrži konstantni region lakog lanca i/ili teškog lanca.
6.    Sklerostin-vezujuće antitelo prema zahtevu 5, koje je IgG.
7.    Sklerostin-vezujuće antitelo prema zahtevu 5, koje sadrži konstantni region humanog IgG4 ili humanog IgG2.
8.    Sklerostin-vezujuće antitelo prema zahtevu 1, koje ima teške lance SEQ 1D NO: 137 i lake lance SEQ ID NO: 133.
9.    Sklerostin-vezujuće antitelo prema zahtevu 1, koje ima teške lance SEQ ID NO: 145 ili 392 i lake lance SEQ ID NO: 141.
10.    Sklerostin-vezujuće antitelo prema ma kom od zahteva 1 do 4, naznačeno time što je navedeno antitelo fragment sklerostin-vezujućeg antitela, koji sadrži šest CDR-a, navedenih u zahtevu 1.
11. Sklerostin-vezujuće antitelo prema ma kom od zahteva 1 do 9, koje je kompletno antitelo.
12.    Sklerostin-vezujuće antitelo prema zahtevu 10, naznačeno time što je navedeno antitelo F(ab’)2, Fab, Fab’ ili Fv fragment.
13.    Sklerostin-vezujuće antitelo prema ma kom od zahteva 1 do 7, koje je humanizovano antitelo ili himerično antitelo.
14.    Sklerostin-vezujuće antitelo prema ma kom od prethodnih zahteva, naznačeno time što navedeno antitelo ima konstantu disocijacije za humani sklerostin, kako je izmereno posredstvom površinske plazmon rezonance, koja je manja ili jednaka 1 x 10-9 M, manja ili jednaka 1 x 10-10 M, manja ili jednaka 1 x 10-11 M ili je manja ili jednaka 1 x 10-12 M.
15.    Sklerostin-vezujuće antitelo prema ma kom od prethodnih zahteva, za koje je vezan jedan ili više efektorskih ili reporterskih molekula.
16.    Sklerostin-vezujuće antitelo prema ma kom od prethodnih zahteva, naznačeno time što navedeno antitelo može povećati najmanje jedno od sledećih: formiranje kosti, mineralna gustina kosti, mineralni sadržaj kosti, koštana masa, kvalitet kosti i jačina kosti kod sisara.
17.    Sklerostin-vezujuće antitelo prema ma kom od prethodnih zahteva, naznačeno time što navedeno antitelo može blokirati inhibitomo dejstvo sklerostina u testu mineralizaeije na ćelijskoj bazi.
18.    Izolovana polinukleotidna sekvenca koja kodira sklerostin-vezujuće antitelo prema ma kom od zahteva 1 do 17.
19.    Klonirajući ili ekspresioni vektor koji sadrži jednu ili više polinukleotidnih sekvenci prema zahtevu 18.
20.    Vektor prema zahtevu 19, naznačen time što vektor sadrži najmanje jednu sekvencu, datu u SEQ ID NO: 134, 136, 138,140, 142, 144, 146, 148 i 379.
21. Ćelija domaćina koja sadrži jedan ili više klonirajućih ili ekspresionih vektora prema zahtevu 19 ili zahtevu 20.
22. Postupak za proizvodnju sklerostin-vezujućeg antitela prema ma kom od zahteva 1 do 17, koji obuhvata kultivaciju domaćinske ćelije prema zahtevu 21 i izolovanje sklerostin-vezujućeg antitela.
23.    Farmaceutska smeša koja sadrži sklerostin-vezujuće antitelo prema ma kom od zahteva 1 do 17 u kombinaciji sa jednim ili više farmaceutski prihvatljivih ekscipijenata, razblaživača i nosača.
24.    Farmaceutska smeša prema zahtevu 23, koja dodatno sadrži druge aktivne sastojke.
25.    Sklerostin-vezujuće antitelo prema ma kom od zahteva 1 do 17 ili farmaceutska smeša prema zahtevu 23 ili zahtevu 24, za korišćenje u postupku lečenja koštanog poremećaja povezanog sa najmanje jednim od sledećih: slabo formiranje kosti, slaba mineralna gustina kosti, slab mineralni sadržaj kosti, mala koštana masa, slab kvalitet kosti i slaba jačina kosti kod ispitanika sisara, naznačeno time što postupak obuhvata davanje ispitaniku kome je takav tretman potreban količine navedenog antitela koja je dovoljna za povećanje barem jednog od sledećih: formiranje kosti, mineralna gustina kosti, mineralni sadržaj kosti, koštana masa, kvalitet kosti i jačina kosti.
26.    Antitelo ili farmaceutska smeša prema zahtevu 25 za navedenu upotrebu, naznačeni time što je koštani poremećaj: osteopenija, osteoporoza, gubitak kosti ili abnormalni rast ili razvoj kosti, izazvan najmanje jednim od: ahondroplazije, kleidokranijalne disostoze, enhondromatoze, fibrozne displazije, Gaucherove bolesti, hipofosfatemijskog rahitisa, Marfanovog sindroma, multiple hereditame egzotoze, neurofibromatoze, osteogenesis imperfecta, osteopoikiloze, sklerotskih lezija, pseudoartroze, pijogenog osteomijelitisa, periodontalne bolesti, gubitka kosti indukovanog antiepileptičnim lekovima, primarnog i sekundarnog hiperparatiroidizma, familijarnih hiperparatiroidnih sindroma, gubitka kosti indukovanog bestežinskim stanjem, osteoporoze kod muškaraca, gubitka kosti u postmenopauzi, osteoartritisa, renalne osteodistrofije, infiltrativnih poremećaja kosti, gubitka oralne kosti, osteonekroze vilice, juvenilne Pagetove bolesti, meloreostoze, metaboličkih koštanih bolesti, mastocitoze, anemije/bolesti srpastih ćelija, gubitka kosti povezanog sa transplantacijom organa, gubitka kosti povezanog sa transplantacijom bubrega, sistemskog lupusa eritematozusa, ankilozirajućeg spondilitisa, epilepsije, juvenilnog artritisa, talasemije, mukopolisaharidoza, Fabrijeve bolesti, Turnerovog sindroma, Downovog sindroma, Klinefelterovog sindroma, gube, Perthesove bolesti, adolescentne idiopatske skolioze, multisistemske inflamatome bolesti s početkom u detinjstvu, sindroma Winchester, Menkesove bolesti, Wilsonove bolesti, ishemijske bolesti kosti (kao što je Legg-Calve-Perthesova bolest, regionalna migratoma osteoporoza), anemičnih stanja, stanja izazvanih steroidima, gubitka kosti indukovanog glukokortikoidima, gubitka kosti indukovanog heparinom, poremećaja koštane srži, skorbuta, malnutricije, deficijencije kalcijuma, alkoholizma, hronične bolesti jetre, stanja posle menopauze, hroničnih inflamatomih stanja, reumatoidnog artritisa, inflamatome bolesti creva, ulceroznog kolitisa, inflamatomog kolitisa, Crohnove bolesti, oligomenoreje, amenoreje, trudnoće, šećerne bolesti, hipertireoze, poremećaja štitne žlezde, paratiroidnih poremećaja, Cushingove bolesti, akromegalije, hipogonadizma, imobilizacije ili nekretanja, sindroma refleksne simpatičke distrofije, regionalne osteoporoze, osteomalacije, gubitka kosti povezanog sa zamenom zgloba, gubitka kosti povezanog sa HlV-om, gubitka kosti povezanog sa nedostatkom hormona rasta, gubitka kosti povezanog sa cističnom fibrozom, gubitka kosti povezanog sa hemioterapijom, gubitka kosti indukovanog tumorom, gubitka kosti povezanog sa malignom bolešću, hormon ablativnog gubitka kosti, multiplog mijeloma, gubitka kosti izazvanog lekovima, anoreksije nervoze, gubitka facijalne kosti povezane sa bolešću, gubitka kranijalne kosti povezanog sa bolešću, gubitka vilične kosti povezanog sa bolešću, gubitka kosti lobanje povezanog sa bolešću, gubitka kosti povezanog sa starenjem, gubitka facijalne kosti povezanog sa starenjem, gubitka kranijalne kosti povezanog sa starenjem, gubitka kosti vilice povezanog sa starenjem, gubitka kosti lobanje povezanog sa starenjem i gubitka kosti povezanog sa svemirskim putovanjem.
27.    Antitelo ili farmaceutska smeša prema zahtevu 25 za navedeno korišćenje, naznačeno time što je koštani poremećaj osteoporoza.
28.    Antitelo prema ma kom od zahteva 1 do 17 ili farmaceutska smeša prema zahtevu 23 ili 24, za korišćenje u postupku poboljšanja ishoda kod sisara koji se podvrgava jednom ili više od sledećih: ortopedska procedura, dentalna procedura, implant hirurgija, zamena zgloba, stavljanje koštanih graftova, kozmetička hirurgija kosti i obnova kosti, kao što je zaceljivanje frakture, zaceljivanje bez šava, odloženo zaceljivanje sa šavom i facijalna rekonstrukcija, pri čemu navedni postupak obuhvata primenu navedenog antitela ili smeše navedenom sisaru pre, tokom i/ili nakon navedene procedure, zamene, grafta, hirurške intervencije ili obnove.
29.    Dijagnostički komplet koji sadrži antitelo prema ma kom od zahteva 1 do 17.
30.    Korišćenje antitela prema ma kom od zahteva 1 do 17 za proizvodnju leka za lečenje koštanog premećaja, povezanog sa najmanje jednim od sledećih: slabo formiranje kosti, slaba mineralna gustina kosti, slab mineralni sadržaj kosti, mala koštana masa, slab kvalitet kosti i slaba jačina kosti kod ispitanika sisara.
31.    Korišćenje prema zahtevu 30, naznačeno time što je koštani poremećaj: osteopenija, osteoporoza, gubitak kosti ili abnormalni rast ili razvoj kosti, izazvan najmanje jednim od: ahondroplazije, kleidokranijalne disostoze, enhonđromatoze, fibrozne displazije, Gaucherove bolesti, hipofosfatemijskog rahitisa, Marfanovog sindroma, multiple hereditame egzotoze, neurofibromatoze, osteogenesis imperfecta, osteopetroze, osteopoikiloze, sklerotskih lezija, pseudoartroze, pijogenog osteomijelitisa, periodontalne bolesti, gubitka kosti indukovanog antiepileptičnim lekovima, primarnog i sekundarnog hiperparatiroidizma, familijarnih hiperparatiroidnih sindroma, gubitka kosti indukovanog bestežinskim stanjem, osteoporoze kod muškaraca, gubitka kosti u postmenopauzi, osteoartritisa, renalne osteodistrofije, infiltrativnih poremećaja kosti, gubitka oralne kosti, osteonekroze vilice, juvenilne Pagetove bolesti, meloreostoze, metaboličkih koštanih bolesti, mastocitoze, anemije/bolesti srpastih ćelija, gubitka kosti povezanog sa transplantacijom organa, gubitka kosti povezanog sa transplantacijom bubrega, sistemskog lupusa eritematozusa, ankilozirajućeg spondilitisa, epilepsije, juvenilnog artritisa, talasemije, mukopolisaharidoza, Fabrijeve bolesti, Tumerovog sindroma, Downovog sindroma, Klinefelterovog sindroma, gube, Perthesove bolesti, adolescentne idiopatske skolioze, multisistemske inflamatome bolesti s početkom u detinjstvu, sindroma Winchester, Menkesove bolesti, Wilsonove bolesti, ishemijske bolesti kosti (kao što je Legg-Calve-Perthesova bolest, regionalna migratoma osteoporoza), anemičnih stanja, stanja izazvanih steroidima, gubitka kosti indukovanog glukokortikoidima, gubitka kosti indukovanog heparinom, poremećaja koštane srži, skorbuta, malnutricije, deficijencije kalcijuma, alkoholizma, hronične bolesti jetre, stanja posle menopauze, hroničnih inflamatomih stanja, reumatoidnog artritisa, inflamatome bolesti creva, ulceroznog kolitisa, inflamatomog kolitisa, Crohnove bolesti, oligomenoreje, amenoreje, tmdnoće, šećerne bolesti, hipertireoze, poremećaja štitne žlezde, paratiroidnih poremećaja, Cushingove bolesti, akromegalije, hipogonadizma, imobilizacije ili nekretanja, sindroma refleksne simpatičke distrofije, regionalne osteoporoze, osteomalacije, gubitka kosti povezanog sa zamenom zgloba, gubitka kosti povezanog sa HlV-om, gubitka kosti povezanog sa nedostatkom hormona rasta, gubitka kosti povezanog sa cističnom fibrozom, gubitka kosti povezanog sa hemioterapijom, gubitka kosti indukovanog tumorom, gubitka kosti povezanog sa malignom bolešću, hormon ablativnog gubitka kosti, multiplog mijeloma, gubitka kosti izazvanog lekovima, anoreksije nervoze, gubitka facijalne kosti povezane sa bolešću, gubitka kranijalne kosti povezanog sa bolešću, gubitka vilične kosti povezanog sa bolešću, gubitka kosti lobanje povezanog sa bolešću, gubitka kosti povezanog sa starenjem, gubitka facijalne kosti povezanog sa starenjem, gubitka kranijalne kosti povezanog sa starenjem, gubitka kosti vilice povezanog sa starenjem, gubitka kosti lobanje povezanog sa starenjem i gubitka kosti povezanog sa svemirskim putovanjem.
32.    Korišćenje prema zahtevu 30, naznačeno time što je poremećaj kosti osteoporoza.
33.    Korišćenje antitela prema ma kom od zahteva 1 to 17 za proizvodnju leka za poboljšanja ishoda kod sisara koji se podvrgava jednom ili više od sledećih: ortopedska procedura, dentalna procedura, implant hirurgija, zamena zgloba, stavljanje koštanih graftova, kozmetička hirurgija kosti i obnova kosti, kao što je zaceljivanje frakture, zaceljivanje bez šava, odloženo zaceljivanje sa šavom i facijalna rekonstrukcija, pri čemu je lek za primenu navedenom sisaru pre, tokom i/ili nakon navedene procedure, zamene, grafita, hirurške intervencije ili obnove.
MEP-2013-358A 2005-05-03 2006-04-28 Sklerostin vezujuća sredstva ME02085B (me)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US67758305P 2005-05-03 2005-05-03
US77684706P 2006-02-24 2006-02-24
US78224406P 2006-03-13 2006-03-13
US79264506P 2006-04-17 2006-04-17
US11/411,003 US7592429B2 (en) 2005-05-03 2006-04-25 Sclerostin-binding antibody
EP06751903.3A EP1891101B8 (en) 2005-05-03 2006-04-28 Sclerostin binding agents
PCT/US2006/016441 WO2006119107A2 (en) 2005-05-03 2006-04-28 Sclerostin binding agents

Publications (1)

Publication Number Publication Date
ME02085B true ME02085B (me) 2014-02-28

Family

ID=36992590

Family Applications (2)

Application Number Title Priority Date Filing Date
MEP-2013-358A ME02085B (me) 2005-05-03 2006-04-28 Sklerostin vezujuća sredstva
MEP-2015-373A ME02247B (me) 2005-05-03 2006-04-28 Sklerostin vezujuća sredstva

Family Applications After (1)

Application Number Title Priority Date Filing Date
MEP-2015-373A ME02247B (me) 2005-05-03 2006-04-28 Sklerostin vezujuća sredstva

Country Status (42)

Country Link
US (8) US7592429B2 (me)
EP (7) EP2336163A1 (me)
JP (4) JP5462484B2 (me)
KR (4) KR101653122B1 (me)
CN (4) CN103435698B (me)
AR (1) AR053266A1 (me)
AU (2) AU2006242431B2 (me)
BR (2) BR122020023315B1 (me)
CA (2) CA2947080A1 (me)
CR (1) CR9524A (me)
CY (4) CY1114350T1 (me)
DK (3) DK2325199T3 (me)
EA (2) EA037044B1 (me)
ES (4) ES2689143T3 (me)
FR (1) FR20C1010I2 (me)
GE (2) GEP20125594B (me)
GT (1) GT200600186A (me)
HR (3) HRP20211904T1 (me)
HU (3) HUE025530T2 (me)
IL (3) IL187106A (me)
LT (2) LT3670528T (me)
LU (1) LUC00151I2 (me)
MA (1) MA29528B1 (me)
ME (2) ME02085B (me)
MX (3) MX2007013759A (me)
MY (1) MY163480A (me)
NL (1) NL301034I2 (me)
NO (4) NO346914B1 (me)
NZ (2) NZ591636A (me)
PE (1) PE20070317A1 (me)
PH (1) PH12015501848A1 (me)
PL (3) PL1891101T3 (me)
PT (3) PT3670528T (me)
RS (3) RS52919B (me)
SG (1) SG10201403400UA (me)
SI (3) SI2325199T1 (me)
TN (1) TNSN07406A1 (me)
TW (5) TWI494320B (me)
UA (1) UA123695C2 (me)
UY (2) UY38207A (me)
WO (1) WO2006119107A2 (me)
ZA (1) ZA200709480B (me)

Families Citing this family (222)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040009535A1 (en) * 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
US6395511B1 (en) * 1998-11-27 2002-05-28 Darwin Discovery, Ltd. Nucleic acids encoding a novel family of TGF-β binding proteins from humans
WO2003087763A2 (en) 2002-04-03 2003-10-23 Celltech R & D, Inc. Association of polymorphisms in the sost gene region with bone mineral density
US7585501B2 (en) 2002-06-14 2009-09-08 Stowers Institute For Medical Research Compositions and methods for treating kidney disease
US7893218B2 (en) * 2003-06-16 2011-02-22 Stowers Institute For Medical Research Antibodies that specifically bind SOST peptides
WO2003106657A2 (en) 2002-06-14 2003-12-24 Stowers Institute For Medical Research Wise/sost nucleic acid sequences and amino acid sequences
EP1636270B1 (en) 2003-06-16 2016-07-20 UCB Pharma S.A. Antibodies specific for sclerostin and methods for increasing bone mineralization
US8461155B2 (en) * 2003-09-22 2013-06-11 University Of Connecticut Sclerostin and the inhibition of WNT signaling and bone formation
ITMI20050739A1 (it) * 2005-04-22 2006-10-23 Effebi Spa Piastrina di connsessione valvola-attuatore
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
US7592429B2 (en) * 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
ITTO20050905A1 (it) * 2005-12-23 2007-06-24 Univ Degli Studi Torino Leganti sintetici capaci di legare l'ocratossina e relativi usi
WO2008061013A2 (en) * 2006-11-10 2008-05-22 Amgen Inc. Antibody-based diagnostics and therapeutics
EP2094731A2 (en) * 2006-11-10 2009-09-02 UCB Pharma S.A. Anti human sclerostin antibodies
US8178099B2 (en) 2006-12-29 2012-05-15 Osteogenex Inc. Methods of altering bone growth by administration of sost or wise antagonist or agonist
CN101646457B (zh) * 2007-03-20 2013-05-01 伊莱利利公司 抗硬骨素抗体
US7977313B2 (en) * 2007-04-27 2011-07-12 Affinergy, Inc. Methods and compositions for promoting localization of pharmaceutically active agents to bone
EP2599791A1 (en) * 2007-04-27 2013-06-05 Genentech, Inc. Potent, stable and non-immunosuppressive anti-CD4 antibodies
MX2010002249A (es) * 2007-08-31 2010-03-17 Amgen Inc Formulacion de proteina de estado solido.
US7981415B2 (en) * 2007-09-07 2011-07-19 Cisthera, Inc. Humanized PAI-1 antibodies
CL2008002775A1 (es) * 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
ES2750254T3 (es) 2007-09-27 2020-03-25 Amgen Inc Formulaciones farmacéuticas
TWI489993B (zh) 2007-10-12 2015-07-01 Novartis Ag 骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法
EP3381445B1 (en) 2007-11-15 2023-10-25 Amgen Inc. Aqueous formulation of antibody stablised by antioxidants for parenteral administration
BRPI0819688A2 (pt) * 2007-12-14 2015-06-16 Amgen Inc Processo para tratamento de fratura óssea com anticorpos anti-esclerostina.
CA2721052C (en) 2008-04-11 2023-02-21 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
EP2899209A1 (en) * 2008-04-29 2015-07-29 Abbvie Inc. Dual Variable Domain Immunoglobulins and uses thereof
EP2297208A4 (en) 2008-06-03 2012-07-11 Abbott Lab DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND ITS USES
BRPI0913406A2 (pt) 2008-06-03 2018-01-09 Abbott Lab imunoglobulinas de domínio variável duplo e usos das mesmas
US8822645B2 (en) 2008-07-08 2014-09-02 Abbvie Inc. Prostaglandin E2 dual variable domain immunoglobulins and uses thereof
PT2398498T (pt) * 2009-02-17 2018-12-03 Ucb Biopharma Sprl Moléculas de anticorpo tendo especificidade para ox40 humano
WO2010115932A1 (en) 2009-04-08 2010-10-14 Novartis Ag Combination for the treatment of bone loss
MX2011011670A (es) * 2009-05-01 2011-11-18 Abbott Lab Inmunoglobulinas de dominio variable dual y usos de las mismas.
US9775819B2 (en) * 2009-09-16 2017-10-03 R.P. Scherer Technologies, Llc Oral solid dosage form containing nanoparticles and process of formulating the same using fish gelatin
US8716450B2 (en) * 2009-10-15 2014-05-06 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
US9662271B2 (en) 2009-10-23 2017-05-30 Amgen Inc. Vial adapter and system
UY32979A (es) * 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
KR20130010123A (ko) 2010-04-07 2013-01-25 아비에 인코포레이티드 ＴＮＦ-α 결합 단백질
CA2795886A1 (en) 2010-04-16 2011-10-20 Novartis Ag Methods and compositions for improving implant osseointegration
SMT202000095T1 (it) 2010-05-14 2020-03-13 Amgen Inc Formulazioni di anticorpi anti-sclerostina ad alta concentrazione
US9403882B2 (en) * 2010-06-07 2016-08-02 Joshua Rabbani Sulfation of Wnt pathway proteins
CA2800919C (en) 2010-06-07 2019-01-15 Amgen Inc. Drug delivery device
US9493541B2 (en) * 2010-06-07 2016-11-15 Joshua Rabbani Antibodies specific for sulfated sclerostin
US9617323B2 (en) 2010-06-07 2017-04-11 Joshua Rabbani Sulfonated sclerostin, antibodies, epitopes and methods for identification and use therefor
US11167011B2 (en) 2010-06-07 2021-11-09 Enzo Biochem, Inc. Methods for treating bone loss using sclerostin peptides
TW201206473A (en) 2010-08-03 2012-02-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
PE20140229A1 (es) 2010-08-26 2014-03-27 Abbvie Inc Inmunoglobulinas con dominio variable dual y usos de las mismas
EP2632951B1 (en) 2010-10-27 2017-08-02 Amgen Inc. Dkk1 antibodies and methods of use
JP2014500712A (ja) * 2010-11-02 2014-01-16 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリンおよびその使用
LT3757126T (lt) 2010-11-05 2025-12-10 Novartis Ag Psoriazinio artrito gydymo būdas, panaudojant il-17 antagonistus
CN103328632A (zh) 2010-11-30 2013-09-25 中外制药株式会社 与多分子的抗原重复结合的抗原结合分子
JP6147670B2 (ja) * 2010-12-22 2017-06-14 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド 改善された半減期を有する修飾された抗体
AU2012223358A1 (en) 2011-03-01 2013-09-05 Amgen Inc. Sclerostin and DKK-1 bispecific binding agents
AU2012236962B2 (en) 2011-03-25 2017-05-11 Amgen Inc. Anti-sclerostin antibody crystals and formulations thereof
CA2831100C (en) 2011-03-31 2020-02-18 Mark Dominis Holt Vial adapter and system
EP2699261B1 (en) 2011-04-19 2018-07-11 Amgen Inc. Method for treating osteoporosis
CA2833748C (en) 2011-04-20 2019-07-16 Amgen Inc. Autoinjector apparatus
PH12013502201A1 (en) 2011-04-25 2014-01-13 Daiichi Sankyo Co Ltd Anti-b7-h3 antibody
WO2012149246A1 (en) 2011-04-29 2012-11-01 Novartis Ag Methods of treating squamous cell carcinoma related applications
EP2739311B9 (en) * 2011-08-04 2018-09-19 Amgen Inc. Method for treating bone gap defects
LT3045189T (lt) 2011-10-14 2018-06-25 Amgen Inc. Inžektorius ir surinkimo būdas
IN2014CN03936A (me) 2011-10-24 2015-09-04 Abbvie Inc
CN104203978A (zh) * 2011-10-24 2014-12-10 艾伯维股份有限公司 针对硬化蛋白的免疫结合剂
HK1200321A1 (en) 2011-10-24 2015-08-07 Abbvie Inc. Bispecific immunobinders directed against tnf and il-17
UA112203C2 (uk) 2011-11-11 2016-08-10 Юсб Фарма С.А. Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини
EA202091676A1 (ru) * 2011-12-28 2021-01-29 Эмджен Инк. Способ лечения потери костной массы альвеолярного отростка посредством применения антител к склеростину
TW201333035A (zh) 2011-12-30 2013-08-16 Abbvie Inc 針對ｉｌ－１３及／或ｉｌ－１７之雙特異性結合蛋白
BR112014022692A8 (pt) 2012-03-14 2021-07-20 Regeneron Pharma molécula de ligação de antígeno multiespecífica
EP2869844B2 (en) * 2012-07-05 2023-06-21 UCB Pharma S.A. Treatment for bone diseases
UY35110A (es) 2012-11-01 2014-05-30 Abbvie Inc Inmunoglobulinas de dominio variable dual anti-vegf/dll4 y usos de las mismas
US12115341B2 (en) 2012-11-21 2024-10-15 Amgen Inc. Drug delivery device
UY35148A (es) * 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
WO2014118705A1 (en) 2013-01-31 2014-08-07 Novartis Ag Methods of treating chronic kidney disease-mineral and bone disorder using sclerostin antagonists
US9708375B2 (en) 2013-03-15 2017-07-18 Amgen Inc. Inhibitory polypeptides specific to WNT inhibitors
CA2904661C (en) 2013-03-15 2022-03-15 Amgen Inc. Drug cassette, autoinjector, and autoinjector system
CA2904448A1 (en) 2013-03-15 2014-09-18 Tariq Ghayur Dual specific binding proteins directed against il-1.beta. and/or il-17
EA201591495A1 (ru) * 2013-03-18 2016-05-31 Биосерокс Продактс Б.В. Гуманизированные антитела против cd134 (ox40) и применения указанных антител
PL2976359T5 (pl) * 2013-03-20 2022-07-18 Genzyme Corporation Sposoby leczenia wrodzonej łamliwości kości
IL292270B2 (en) 2013-03-22 2024-04-01 Amgen Inc Injector and method of assembly
WO2014155278A2 (en) 2013-03-26 2014-10-02 Novartis Ag Methods of treating autoimmune diseases using il-17 antagonists
EP3041863A4 (en) 2013-09-05 2017-08-16 Amgen Inc. Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
MX2016005315A (es) 2013-10-24 2016-08-11 Amgen Inc Sistema de administracion de farmacos con control sensible a la temperatura.
SG11201602876WA (en) 2013-10-24 2016-05-30 Amgen Inc Injector and method of assembly
WO2015087187A1 (en) 2013-12-10 2015-06-18 Rinat Neuroscience Corp. Anti-sclerostin antibodies
WO2015119906A1 (en) 2014-02-05 2015-08-13 Amgen Inc. Drug delivery system with electromagnetic field generator
CN110642944B (zh) * 2014-03-07 2021-06-11 神州细胞工程有限公司 一种中和人感染h7n9甲型流感病毒的抗体及其用途
ES2861600T3 (es) 2014-04-04 2021-10-06 Mayo Found Medical Education & Res Isotipaje de inmunoglobulinas usando masa molecular precisa
KR102496507B1 (ko) 2014-05-07 2023-02-03 암겐 인코포레이티드 충격 감소 요소들을 가진 자동 주사기
CA2949237C (en) 2014-05-16 2022-08-23 Amgen Inc. Assay for detecting th1 and th2 cell populations
KR20220143782A (ko) 2014-06-03 2022-10-25 암겐 인코포레이티드 약물 전달 디바이스의 사용자를 보조하기 위한 디바이스들 및 방법들
MX2021014323A (es) 2014-10-14 2023-02-02 Amgen Inc Dispositivo de inyección de fármaco con indicadores visuales y audibles.
CN114569716A (zh) 2014-10-23 2022-06-03 美国安进公司 降低药物制剂的粘度
WO2016094881A2 (en) 2014-12-11 2016-06-16 Abbvie Inc. Lrp-8 binding proteins
MA41142A (fr) 2014-12-12 2017-10-17 Amgen Inc Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement
US11357916B2 (en) 2014-12-19 2022-06-14 Amgen Inc. Drug delivery device with live button or user interface field
EP3848072A1 (en) 2014-12-19 2021-07-14 Amgen Inc. Drug delivery device with proximity sensor
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
CA3069716C (en) 2015-02-17 2021-11-09 Amgen Inc. Drug delivery device with vacuum assisted securement and/or feedback
US11806509B2 (en) 2015-02-27 2023-11-07 Amgen Inc. Drug delivery device having a needle guard mechanism with a turnable threshold of resistance to needle guard movement
PT3269735T (pt) * 2015-03-13 2020-12-04 Shanghai hengrui pharmaceutical co ltd Anticorpo antiesclerotina, fragmanto de ligação a antigénio e seus usos médicos
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
CN107849131A (zh) 2015-07-06 2018-03-27 瑞泽恩制药公司 多特异性抗原结合分子及其用途
US20190135929A1 (en) 2015-08-28 2019-05-09 The General Hospital Corporation Agonistic anti-tumor necrosis factor receptor 2 antibodies
WO2017039786A1 (en) 2015-09-02 2017-03-09 Amgen Inc. Syringe assembly adapter for a syringe
EP3386573B1 (en) 2015-12-09 2019-10-02 Amgen Inc. Auto-injector with signaling cap
WO2017120178A1 (en) 2016-01-06 2017-07-13 Amgen Inc. Auto-injector with signaling electronics
BR112018067522A2 (pt) 2016-03-01 2019-02-05 Univ Of Rijeka Faculty Of Medicine anticorpos específicos para receptor de poliovírus humano (pvr)
GB201604124D0 (en) * 2016-03-10 2016-04-27 Ucb Biopharma Sprl Pharmaceutical formulation
DK3429663T3 (da) 2016-03-15 2020-09-28 Amgen Inc Reduktion af sandsynligheden for glasbrud i anordninger til indgivelse af lægemidler
HUE052869T2 (hu) * 2016-03-17 2021-05-28 Tillotts Pharma Ag TNF-ellenes alfa-antitestek és ezek funkcionális fragmentjei
EP3448891A1 (en) 2016-04-28 2019-03-06 Regeneron Pharmaceuticals, Inc. Methods of making multispecific antigen-binding molecules
US11541168B2 (en) 2016-04-29 2023-01-03 Amgen Inc. Drug delivery device with messaging label
US11389588B2 (en) 2016-05-02 2022-07-19 Amgen Inc. Syringe adapter and guide for filling an on-body injector
WO2017197222A1 (en) 2016-05-13 2017-11-16 Amgen Inc. Vial sleeve assembly
WO2017200989A1 (en) 2016-05-16 2017-11-23 Amgen Inc. Data encryption in medical devices with limited computational capability
US11541176B2 (en) 2016-06-03 2023-01-03 Amgen Inc. Impact testing apparatuses and methods for drug delivery devices
WO2018004842A1 (en) 2016-07-01 2018-01-04 Amgen Inc. Drug delivery device having minimized risk of component fracture upon impact events
KR20190037261A (ko) 2016-08-08 2019-04-05 암젠 인크 항-스클레로스틴 항체를 사용한 결합 조직 부착 개선 방법
US20190328965A1 (en) 2016-08-17 2019-10-31 Amgen Inc. Drug delivery device with placement detection
KR102505384B1 (ko) * 2016-08-31 2023-03-06 에이껜 가가꾸 가부시끼가이샤 다른 방식으로 항원을 고정화한 항원 담지 불용성 담체 입자를 사용하는 항체 측정법, 항체 측정용 시약
EP3532127A1 (en) 2016-10-25 2019-09-04 Amgen Inc. On-body injector
WO2018089305A1 (en) 2016-11-08 2018-05-17 University Of Miami Anti-secretogranin iii (scg3) antibodies and uses thereof
JP7050335B2 (ja) 2016-12-21 2022-04-08 メレオ バイオファーマ ３ リミテッド 骨形成不全症の処置における抗スクレロスチン抗体の使用
WO2018115879A1 (en) 2016-12-21 2018-06-28 Mereo Biopharma 3 Limited Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
JP2020503976A (ja) 2017-01-17 2020-02-06 アムジエン・インコーポレーテツド 注入デバイスならびに関連する使用および組立方法
WO2018139623A1 (en) * 2017-01-30 2018-08-02 Chugai Seiyaku Kabushiki Kaisha Anti-sclerostin antibodies and methods of use
EP3582829A1 (en) 2017-02-17 2019-12-25 Amgen Inc. Insertion mechanism for drug delivery device
CA3048520A1 (en) 2017-02-17 2018-08-23 Amgen Inc. Drug delivery device with sterile fluid flowpath and related method of assembly
JP7377596B2 (ja) 2017-02-22 2023-11-10 アムジエン・インコーポレーテツド 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法
JP2020508803A (ja) 2017-03-06 2020-03-26 アムジエン・インコーポレーテツド 作動防止特徴部を備える薬物送達デバイス
US11571511B2 (en) 2017-03-07 2023-02-07 Amgen Inc. Insertion mechanism and method of inserting a needle of a drug delivery device
KR102893480B1 (ko) 2017-03-09 2025-11-28 암겐 인코포레이티드 약물 전달 장치용 삽입 메커니즘
CA3056011A1 (en) 2017-03-14 2018-09-20 Amgen Inc. Control of total afucosylated glycoforms of antibodies produced in cell culture
HUE063805T2 (hu) 2017-03-28 2024-01-28 Amgen Inc Dugattyúrúd és fecskendõ összeállító rendszer és eljárás
KR102769634B1 (ko) * 2017-04-27 2025-02-19 테사로, 인코포레이티드 림프구 활성화 유전자-3 (lag-3)에 대한 항체 작용제 및 그의 용도
US12103979B2 (en) 2017-04-28 2024-10-01 Amgen Inc. N-acetylated and non-acetylated dipeptides containing arginine to reduce the viscosity of viscous compositions of therapeutic polypeptides
AU2018282077B2 (en) 2017-06-08 2023-11-23 Amgen Inc. Torque driven drug delivery device
CA3061982A1 (en) 2017-06-08 2018-12-13 Amgen Inc. Syringe assembly for a drug delivery device and method of assembly
MA49447A (fr) 2017-06-22 2020-04-29 Amgen Inc Réduction des impacts/chocs d'activation d'un dispositif
WO2018237225A1 (en) 2017-06-23 2018-12-27 Amgen Inc. Electronic drug delivery device comprising a cap activated by a switch assembly
MA49562A (fr) 2017-07-14 2020-05-20 Amgen Inc Système d'insertion-rétractation d'aiguille présentant un système à ressort en double torsion
MA49626A (fr) 2017-07-21 2020-05-27 Amgen Inc Élément d'étanchéité perméable aux gaz pour récipient à médicament et procédés d'assemblage
WO2019022950A1 (en) 2017-07-25 2019-01-31 Amgen Inc. DRUG DELIVERY DEVICE WITH CONTAINER ACCESS SYSTEM AND ASSEMBLY METHOD THEREOF
JP2020528296A (ja) 2017-07-25 2020-09-24 アムジエン・インコーポレーテツド ギヤモジュールを有する薬物送達デバイス及び関連する組立方法
CN109952093B (zh) * 2017-07-27 2022-02-08 江苏恒瑞医药股份有限公司 一种sost抗体药物组合物及其用途
IL271499B2 (en) 2017-08-01 2024-12-01 Amgen Inc Systems and methods for real-time polypeptide sample preparation for mass spectrometry analysis
EA202090380A1 (ru) 2017-08-01 2020-05-21 Эмджен Инк. Системы и способы для выполнения анализа гликанов в образце в режиме реального времени
MA49838A (fr) 2017-08-09 2020-06-17 Amgen Inc Systèm de administration de médicaments avec pression hydraulique-pneumatique de chambre
US11077246B2 (en) 2017-08-18 2021-08-03 Amgen Inc. Wearable injector with sterile adhesive patch
US11103636B2 (en) 2017-08-22 2021-08-31 Amgen Inc. Needle insertion mechanism for drug delivery device
WO2019051047A1 (en) 2017-09-07 2019-03-14 University Of Florida Research Foundation, Inc. CHIMERIC ANTIGEN RECEPTOR T-LYMPHOCYTES EXPRESSING THE INTERLEUKIN-8 RECEPTOR
WO2019055632A1 (en) 2017-09-13 2019-03-21 Mayo Foundation For Medical Education And Research IDENTIFICATION AND MONITORING OF IMMUNOGLOBULIN CHAINS J
US11946937B2 (en) 2017-09-13 2024-04-02 Mayo Foundation For Medical Education And Research Identification and monitoring of apoptosis inhibitor of macrophage
ES2939292T3 (es) 2017-10-04 2023-04-20 Amgen Inc Adaptador de flujo para dispositivo de administración de fármacos
EP3691716B1 (en) 2017-10-06 2023-11-29 Amgen Inc. Drug delivery device with interlock assembly and related method of assembly
US11464903B2 (en) 2017-10-09 2022-10-11 Amgen Inc. Drug delivery device with drive assembly and related method of assembly
WO2019090079A1 (en) 2017-11-03 2019-05-09 Amgen Inc. System and approaches for sterilizing a drug delivery device
US12053618B2 (en) 2017-11-06 2024-08-06 Amgen Inc. Fill-finish assemblies and related methods
JP2021501616A (ja) 2017-11-06 2021-01-21 アムジエン・インコーポレーテツド 配置及び流量検出を備える薬物送達デバイス
MA50557A (fr) 2017-11-10 2020-09-16 Amgen Inc Pistons pour dispositifs d'administration de médicament
WO2019099322A1 (en) 2017-11-16 2019-05-23 Amgen Inc. Autoinjector with stall and end point detection
IL273638B2 (en) 2017-11-16 2024-10-01 Amgen Inc Door latch mechanism for drug delivery device
KR102775717B1 (ko) 2018-03-13 2025-03-06 암젠 인크 질량 분광 분석을 위한 폴리펩티드의 순차적 소화
US12405275B2 (en) 2018-03-13 2025-09-02 Amgen Inc. Methods for the preparation of trypsin-resistant polypeptides for mass spectrometric analysis
CN111954719B (zh) 2018-03-26 2025-07-18 美国安进公司 细胞培养物中产生的抗体的总去岩藻糖基化糖型
KR20200138254A (ko) * 2018-03-30 2020-12-09 암젠 인크 C-말단 항체 변이체
MX2020011487A (es) 2018-04-30 2020-12-07 Regeneron Pharma Anticuerpos y moleculas biespecificas de union al antigeno que se unen a her2 y/o aplp2, conjugados y usos de estos.
US10835685B2 (en) 2018-05-30 2020-11-17 Amgen Inc. Thermal spring release mechanism for a drug delivery device
US11083840B2 (en) 2018-06-01 2021-08-10 Amgen Inc. Modular fluid path assemblies for drug delivery devices
GB201810746D0 (en) 2018-06-29 2018-08-15 Mereo Biopharma 3 Ltd Use of sclerostin antagonist
UY38289A (es) 2018-07-02 2020-01-31 Amgen Inc Proteína de unión al antígeno anti-steap1
CA3103682A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Delivery devices for administering drugs
MA53379A (fr) 2018-07-24 2021-06-02 Amgen Inc Dispositifs d'administration pour l'administration de médicaments
WO2020023336A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Hybrid drug delivery devices with grip portion
WO2020023220A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Hybrid drug delivery devices with tacky skin attachment portion and related method of preparation
MA53320A (fr) 2018-07-31 2021-11-03 Amgen Inc Ensemble de trajet de fluide pour dispositif d'administration de médicament
CA3108693A1 (en) 2018-08-10 2020-02-13 Ashutosh Sharma Method of preparing an antibody pharmaceutical formulation
CA3109954A1 (en) * 2018-08-20 2020-02-27 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor superfamily polypeptides
AU2019347710B2 (en) 2018-09-24 2025-05-08 Amgen Inc. Interventional dosing systems and methods
IL281469B2 (en) 2018-09-28 2024-08-01 Amgen Inc Muscle wire escapement activation assembly for a drug delivery device
US12156991B2 (en) 2018-10-02 2024-12-03 Amgen Inc. Injection systems for drug delivery with internal force transmission
WO2020072846A1 (en) 2018-10-05 2020-04-09 Amgen Inc. Drug delivery device having dose indicator
WO2020081480A1 (en) 2018-10-15 2020-04-23 Amgen Inc. Platform assembly process for drug delivery device
US12053617B2 (en) 2018-10-15 2024-08-06 Amgen Inc. Drug delivery device having damping mechanism
KR20210098454A (ko) 2018-10-30 2021-08-10 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 항-cd79b 항체 및 키메라 항원 수용체 및 사용 방법
US11213620B2 (en) 2018-11-01 2022-01-04 Amgen Inc. Drug delivery devices with partial drug delivery member retraction
TWI831847B (zh) 2018-11-01 2024-02-11 美商安進公司 部分針頭縮回之藥物遞送裝置及其操作方法
US12485219B2 (en) 2018-11-01 2025-12-02 Amgen Inc. Drug delivery devices with partial drug delivery member retraction
TWI852964B (zh) 2018-12-14 2024-08-21 美商安進公司 與依照斜率的蛋白質濃度確定一起使用之系統適用性方法
ES2987091T3 (es) 2019-02-14 2024-11-13 Amgen Inc Sistemas y métodos para preparar una muestra y realizar un ensayo en tiempo real de la muestra
JP7530376B2 (ja) 2019-02-20 2024-08-07 アムジエン・インコーポレーテツド タンパク質の安定性を決定する方法
JP7570341B2 (ja) 2019-03-04 2024-10-21 アムジエン・インコーポレーテツド 高分子量種のインビボでの可逆性
CN109897105B (zh) * 2019-03-22 2022-05-20 天承南运(天津)科技有限公司 Ev71病毒的单克隆抗体、其制备方法及其检测试纸条
EP3948242A1 (en) 2019-03-27 2022-02-09 Amgen Inc. Methods of fingerprinting therapeutic proteins via a two-dimensional (2d) nuclear magnetic resonance technique at natural abundance for formulated biopharmaceutical products
ES3032751T3 (en) 2019-04-24 2025-07-24 Amgen Inc Syringe sterilization verification assemblies and methods
MA56121A (fr) 2019-06-05 2022-04-13 Amgen Inc Procédés d'identification d'attributs de protéines thérapeutiques
JP2022544495A (ja) 2019-08-12 2022-10-19 アムジエン・インコーポレーテツド 抗スクレロスチン抗体製剤
MX2022002149A (es) 2019-08-23 2022-03-17 Amgen Inc Dispositivo de suministro de farmacos con componentes de acoplamiento de capuchon de aguja configurable y metodos relacionados.
CN110499287B (zh) * 2019-08-30 2021-07-23 博雅干细胞科技有限公司 简易制备胎盘间充质干细胞外泌体的方法
BR112022005583A2 (pt) 2019-09-26 2022-09-20 Amgen Inc Métodos para a produção de composições de anticorpos
AU2021264094A1 (en) * 2020-04-30 2022-11-24 Board Of Regents, The University Of Texas System Anti-CD79b antibodies and chimeric antigen receptors and methods of use thereof
CN111537737B (zh) * 2020-05-18 2023-05-12 巴迪泰（广西）生物科技有限公司 降钙素原与c-反应蛋白联合检测试剂盒
EP4162257A1 (en) 2020-06-04 2023-04-12 Amgen Inc. Assessment of cleaning procedures of a biotherapeutic manufacturing process
AU2021343495A1 (en) 2020-09-18 2023-04-27 Amgen Inc. Methods of processing a sample for peptide mapping analysis
AU2021348613A1 (en) * 2020-09-28 2023-06-08 Angitia Incorporated Limited Anti-sclerostin constructs and uses thereof
KR20230087539A (ko) 2020-10-15 2023-06-16 암젠 인크 항체 생산 방법에서의 상대적인 비결합 글리칸
WO2022098595A1 (en) 2020-11-05 2022-05-12 Amgen Inc. Materials and methods for protein processing
KR102255372B1 (ko) 2020-11-24 2021-05-25 (주)발맥스기술 간편 제작 설치 가능 bog 열교환장치
KR20240011135A (ko) 2021-05-21 2024-01-25 암젠 인크 약물 용기를 위한 충전 레시피를 최적화하는 방법
TW202317614A (zh) 2021-06-07 2023-05-01 美商安進公司 使用岩藻糖苷酶控制糖基化蛋白的去岩藻糖基化水平
WO2023059607A1 (en) 2021-10-05 2023-04-13 Amgen Inc. Fc-gamma receptor ii binding and glycan content
WO2023086793A1 (en) 2021-11-09 2023-05-19 Amgen Inc. Production of therapeutic proteins
CN118139882A (zh) * 2022-03-24 2024-06-04 安济盛生物医药有限公司 骨骼肌肉系统疾病的治疗
WO2023215725A1 (en) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
WO2024220916A1 (en) 2023-04-20 2024-10-24 Amgen Inc. Methods of determining relative unpaired glycan content
WO2024259275A1 (en) 2023-06-14 2024-12-19 Bristol-Myers Squibb Company Near real time sialic acid quantitation of glycoproteins
WO2025019728A1 (en) 2023-07-19 2025-01-23 Amgen Inc. Methods of buffer preparation for a therapeutic protein formulation
WO2025038600A1 (en) 2023-08-14 2025-02-20 Amgen Inc. Methods for reducing yellow color
WO2025101602A1 (en) 2023-11-07 2025-05-15 Amgen Inc. Methods of analyzing amino acid content of a therapeutic protein
WO2025101820A1 (en) 2023-11-08 2025-05-15 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
WO2025255028A1 (en) 2024-06-03 2025-12-11 Amgen Inc. High-throughput liquid chromatography-mass spectrometry-based peptide mapping

Family Cites Families (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US32011A (en) 1861-04-09 Coffee-pot
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4411993A (en) 1981-04-29 1983-10-25 Steven Gillis Hybridoma antibody which inhibits interleukin 2 activity
US4427115A (en) 1981-10-19 1984-01-24 Laipply Thomas C One piece alcohol preparation device
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
USRE32011E (en) 1981-12-14 1985-10-22 Scripps Clinic And Research Foundation Ultrapurification of factor VIII using monoclonal antibodies
JPS58117537A (ja) 1982-01-06 1983-07-13 Toray Ind Inc 感光性樹脂組成物
JPS5955608A (ja) * 1982-09-24 1984-03-30 Hitachi Ltd 増幅器
US4543439A (en) 1982-12-13 1985-09-24 Massachusetts Institute Of Technology Production and use of monoclonal antibodies to phosphotyrosine-containing proteins
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US6054561A (en) 1984-02-08 2000-04-25 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
DE3417525C1 (de) 1984-05-11 1986-01-09 Matter + Siegmann Ag, Wohlen Vorrichtung zur quantitativen und qualitativen Erfassung von kohlenwasserstoffhaltigen Schwebeteilchen in Gasen
US4902614A (en) 1984-12-03 1990-02-20 Teijin Limited Monoclonal antibody to human protein C
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5571714A (en) 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
US5177197A (en) 1990-02-27 1993-01-05 Ludwig Institute For Cancer Research Isolated nucleotide sequence expressing human transforming growth factor-β1-binding protein
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
GB9015198D0 (en) * 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
JP3218637B2 (ja) 1990-07-26 2001-10-15 大正製薬株式会社 安定なリポソーム水懸濁液
WO1992002551A1 (en) 1990-08-02 1992-02-20 B.R. Centre Limited Methods for the production of proteins with a desired function
JP2958076B2 (ja) 1990-08-27 1999-10-06 株式会社ビタミン研究所 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
JPH04141095A (ja) 1990-10-02 1992-05-14 Chemo Sero Therapeut Res Inst 組換え抗ｈｉｖ改変抗体および改変抗体の調製方法
US5070108A (en) 1990-10-12 1991-12-03 Trustees Of The University Of Pennsylvania Methods of treating osteoporosis, increasing bone mineral content and preventing the occurrence of compression fractures in a mammal
WO1992006693A1 (en) 1990-10-22 1992-04-30 Fox Chase Cancer Center Dna construct for providing rna therapy
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5795965A (en) * 1991-04-25 1998-08-18 Chugai Seiyaku Kabushiki Kaisha Reshaped human to human interleukin-6 receptor
US5864027A (en) 1993-06-07 1999-01-26 Genentech, Inc. HIV envelope polypeptides
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US5453492A (en) 1993-07-28 1995-09-26 La Jolla Cancer Research Foundation 60 kDa transforming growth factor-β-binding protein and its use to detect or purify TGF-β
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
WO1995030003A2 (en) 1994-04-29 1995-11-09 Creative Biomolecules, Inc. Morphogenic protein-specific cell surface receptors and uses therefor
DE4427221A1 (de) 1994-08-01 1996-02-08 Gsf Forschungszentrum Umwelt Retrovirus-induzierte Osteoklasten-Modulation für die Osteoporose-Therapie
US5846770A (en) 1994-11-22 1998-12-08 Genetics Institute, Inc. DNA molecules encoding human chordin
US6057421A (en) 1994-11-30 2000-05-02 Immpheron, Inc. Variable heavy and light chain regions of murine monoclonal antibody 1F7
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
WO1996039486A1 (en) 1995-06-05 1996-12-12 Human Genome Sciences, Inc. Human ccn-like growth factor
US5738868A (en) 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
BR9710811A (pt) 1996-05-22 1999-08-17 Novopharm Biotech Inc Fragmentos de liga-Æo de antigeno que detecta especificamente c-lulas cancerigenas nucleotideos que codificam os fragmentos e o seu uso para a profilaxia e detec-Æo de c-nceres
US6133426A (en) 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
US6541212B2 (en) * 1997-03-10 2003-04-01 The Regents Of The University Of California Methods for detecting prostate stem cell antigen protein
US5989909A (en) 1997-09-26 1999-11-23 Millennium Biotherapeutics, Inc. Huchordin and uses thereof
AU6959898A (en) 1997-04-11 1998-11-11 David J. Grainger Compounds and therapies for the prevention of vascular and non-vascular pathol ogies
EP1958962A3 (en) 1997-06-12 2013-05-01 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
US6075007A (en) 1997-07-17 2000-06-13 Regeneron Pharmaceuticals, Inc. Modified noggin polypeptide and compositions
CA2297109A1 (en) 1997-08-01 1999-02-11 Genset 5' ests for secreted proteins expressed in muscle and other mesodermal tissues
US6815201B2 (en) 1997-09-08 2004-11-09 The Public Health Research Institute Of The City Of New York, Inc. HIV-1 gp120 V1/V2 domain epitopes capable of generating neutralizing antibodies
GB9818881D0 (en) * 1998-08-28 1998-10-21 Glaxo Group Ltd Compounds
US6544485B1 (en) 2001-01-29 2003-04-08 Sharper Image Corporation Electro-kinetic device with enhanced anti-microorganism capability
US6395511B1 (en) 1998-11-27 2002-05-28 Darwin Discovery, Ltd. Nucleic acids encoding a novel family of TGF-β binding proteins from humans
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
CA2361553A1 (en) * 1999-01-29 2000-08-03 Zhenping Zhu Antibodies specific to kdr and uses thereof
US20090087878A9 (en) * 1999-05-06 2009-04-02 La Rosa Thomas J Nucleic acid molecules associated with plants
EP1185642A2 (en) 1999-06-09 2002-03-13 Genentech, Inc. Compositions and methods for the treatment of tumor
JP4141095B2 (ja) 1999-10-29 2008-08-27 三洋電機株式会社 半導体装置とその製造方法
AU2001241968B2 (en) 2000-03-02 2005-09-15 Amgen Inc. Chordin-like-2 molecules and uses thereof
MXPA02011808A (es) 2000-06-01 2003-04-10 Amgen Inc Polipeptidos de nudos de cistinas: moleculas de polipeptidos encubierto-2 y usos de los mismos.
US20040132021A1 (en) 2000-06-19 2004-07-08 Wendy Balemans Osteolevin gene polymorphisms
CA2421056A1 (en) 2000-09-01 2002-03-28 Genentech, Inc. A polypeptide for use as a diagnostic marker for the presence of colon tumours
ES2332402T5 (es) 2000-10-12 2018-05-14 Genentech, Inc. Formulaciones de proteína concentradas de viscosidad reducida
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
CA2374027A1 (en) 2001-03-13 2002-09-13 The Minister Of National Defence Cloning, expression, sequencing, and functional enhancement of monoclonal scfv antibody against venezuelan equine encephalitis virus(vee)
DE10145772A1 (de) * 2001-09-17 2003-04-10 Bayer Cropscience Ag DELTA·1·-Pyrroline
JP2005512962A (ja) * 2001-09-20 2005-05-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド 抗ｐｄｇｆ抗体および設計抗体の産生方法
AUPR837201A0 (en) 2001-10-19 2001-11-15 BUKILIC, Aleksandar Method and apparatus for cleaning and disinfecting a toothbrush
AU2002357107B2 (en) 2001-12-06 2008-01-10 Biocontrol Systems, Inc. Sample collection and testing system
US20030186915A1 (en) 2002-02-11 2003-10-02 Yang Pan Regulatory polynucleotides and uses thereof
EP1575481A4 (en) * 2002-03-01 2010-01-06 Celltech R & D Inc PROCESS FOR INCREASING OR REDUCING THE BONE DENSITY
WO2003087763A2 (en) 2002-04-03 2003-10-23 Celltech R & D, Inc. Association of polymorphisms in the sost gene region with bone mineral density
FR2838379B1 (fr) 2002-04-12 2005-06-24 Valeo Climatisation Dispositif de purification de l'air de l'habitacle d'un vehicule automobile
US7893218B2 (en) * 2003-06-16 2011-02-22 Stowers Institute For Medical Research Antibodies that specifically bind SOST peptides
WO2003106657A2 (en) 2002-06-14 2003-12-24 Stowers Institute For Medical Research Wise/sost nucleic acid sequences and amino acid sequences
CA2504493C (en) 2002-11-01 2015-12-29 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of preventing infections from bioterrorism agents with immunostimulatory cpg oligonucleotides
DE10255152A1 (de) 2002-11-26 2004-06-03 Von Langen Ursula Lang Schadstoffsauger
US7642238B2 (en) * 2002-12-05 2010-01-05 Shaughnessy John D Molecular determinants of myeloma bone disease and uses thereof
US20040141875A1 (en) 2003-01-15 2004-07-22 Rajiv Doshi System and method for treating microorganisms within motor vehicle heating, ventilation, and air conditioning units
PL378566A1 (pl) 2003-03-14 2006-05-02 Celltech R & D, Inc. Ligandy dla białek wiążących TGF-beta i ich zastosowania
US20050158303A1 (en) 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
CU23403A1 (es) * 2003-04-23 2009-08-04 Centro Inmunologia Molecular Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores
EP1636270B1 (en) 2003-06-16 2016-07-20 UCB Pharma S.A. Antibodies specific for sclerostin and methods for increasing bone mineralization
WO2005018912A1 (de) * 2003-07-21 2005-03-03 Alpla-Werke Alwin Lehner Gmbh & Co. Kg Verfahren zur herstellung eines preformlings für kunststoffflaschen
US8461155B2 (en) 2003-09-22 2013-06-11 University Of Connecticut Sclerostin and the inhibition of WNT signaling and bone formation
WO2005058961A2 (en) * 2003-12-12 2005-06-30 Amgen Inc. Antibodies specific for human galanin, and uses thereof
US20050267233A1 (en) 2004-05-25 2005-12-01 Joshi Ashok V Anti-microbial handle system
MX2007001221A (es) 2004-08-04 2007-03-23 Amgen Inc Anticuerpos para proteina dickkopf-1 (dkk-1).
US7592429B2 (en) * 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
US8003108B2 (en) * 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
EP1981910B1 (en) 2006-01-13 2013-06-26 A Chan Holding B.V. Method for identifying inhibitor of the glypican-sclerostin interaction
EP2094731A2 (en) 2006-11-10 2009-09-02 UCB Pharma S.A. Anti human sclerostin antibodies
WO2008061013A2 (en) 2006-11-10 2008-05-22 Amgen Inc. Antibody-based diagnostics and therapeutics
US8178099B2 (en) 2006-12-29 2012-05-15 Osteogenex Inc. Methods of altering bone growth by administration of sost or wise antagonist or agonist
JP2010526766A (ja) 2007-02-02 2010-08-05 ノバルティス アーゲー 骨関連障害を処置するためのスクレロスチン結合パートナーのモジュレーター
CN101646457B (zh) 2007-03-20 2013-05-01 伊莱利利公司 抗硬骨素抗体
CL2008002775A1 (es) * 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
TWI489993B (zh) 2007-10-12 2015-07-01 Novartis Ag 骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法
WO2009056634A2 (en) 2007-11-02 2009-05-07 Novartis Ag Molecules and methods for modulating low-density-lipoprotein receptor-related protein 6 (lrp6)
BRPI0819688A2 (pt) 2007-12-14 2015-06-16 Amgen Inc Processo para tratamento de fratura óssea com anticorpos anti-esclerostina.
BRPI0913406A2 (pt) 2008-06-03 2018-01-09 Abbott Lab imunoglobulinas de domínio variável duplo e usos das mesmas
WO2010100200A2 (en) 2009-03-05 2010-09-10 Novartis Ag Lyophilised antibody formulation
WO2010100179A2 (en) 2009-03-05 2010-09-10 Novartis Ag Self-forming gel system for sustained drug delivery
WO2010115932A1 (en) 2009-04-08 2010-10-14 Novartis Ag Combination for the treatment of bone loss
WO2010130830A2 (en) 2009-05-15 2010-11-18 Ablynx N.V. Amino acid sequences directed against sclerostin and polypeptides comprising the same for the treatment of bone diseases and disorders
SMT202000095T1 (it) * 2010-05-14 2020-03-13 Amgen Inc Formulazioni di anticorpi anti-sclerostina ad alta concentrazione
WO2012028683A1 (en) 2010-09-02 2012-03-08 Novartis Ag Antibody gel system for sustained drug delivery
EP2632951B1 (en) * 2010-10-27 2017-08-02 Amgen Inc. Dkk1 antibodies and methods of use
AU2012223358A1 (en) * 2011-03-01 2013-09-05 Amgen Inc. Sclerostin and DKK-1 bispecific binding agents
AU2012236962B2 (en) * 2011-03-25 2017-05-11 Amgen Inc. Anti-sclerostin antibody crystals and formulations thereof
EP2739311B9 (en) * 2011-08-04 2018-09-19 Amgen Inc. Method for treating bone gap defects
EA202091676A1 (ru) * 2011-12-28 2021-01-29 Эмджен Инк. Способ лечения потери костной массы альвеолярного отростка посредством применения антител к склеростину
UY35148A (es) * 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
KR20200138254A (ko) * 2018-03-30 2020-12-09 암젠 인크 C-말단 항체 변이체

Also Published As

Publication number Publication date
AU2006242431B2 (en) 2012-11-08
HRP20211904T1 (hr) 2022-03-04
MX2018005512A (es) 2021-11-16
AU2006242476A1 (en) 2006-11-09
FR20C1010I1 (me) 2020-05-01
US20130121997A1 (en) 2013-05-16
US20090304713A1 (en) 2009-12-10
UA123695C2 (uk) 2021-05-19
DK3670528T3 (da) 2021-12-06
PE20070317A1 (es) 2007-04-27
FR20C1010I2 (fr) 2021-03-05
US20200048338A1 (en) 2020-02-13
CN103819558A (zh) 2014-05-28
LUC00151I2 (me) 2021-02-15
NL301034I2 (nl) 2020-05-13
JP5462484B2 (ja) 2014-04-02
HK1198444A1 (en) 2015-04-24
CY1116525T1 (el) 2017-03-15
SI1891101T1 (sl) 2013-10-30
TWI494320B (zh) 2015-08-01
MA29528B1 (fr) 2008-06-02
CN103435698B (zh) 2018-08-31
ES2902548T3 (es) 2022-03-28
KR20150117302A (ko) 2015-10-19
EP3670528A1 (en) 2020-06-24
CN101287756B (zh) 2014-06-25
EP1891101B1 (en) 2013-05-22
HUE025530T2 (en) 2016-04-28
CR9524A (es) 2008-05-21
WO2006119107A3 (en) 2006-12-28
PL3670528T3 (pl) 2022-01-31
TW202323271A (zh) 2023-06-16
NZ563539A (en) 2011-04-29
UY29514A1 (es) 2006-11-30
GEP20166454B (en) 2016-04-11
JP5391360B2 (ja) 2014-01-15
JP2013249303A (ja) 2013-12-12
TW202108605A (zh) 2021-03-01
LUC00151I1 (me) 2020-03-16
EP2325199A1 (en) 2011-05-25
MY163480A (en) 2017-09-15
ES2689143T3 (es) 2018-11-08
CY1114350T1 (el) 2016-08-31
GT200600186A (es) 2007-02-09
US20130203965A1 (en) 2013-08-08
ES2412857T3 (es) 2013-07-12
TW201323438A (zh) 2013-06-16
SI2325199T1 (sl) 2015-07-31
BR122020023315B1 (pt) 2021-06-08
NO20201120A1 (no) 2008-01-30
RS54049B1 (sr) 2015-10-30
HRP20150597T1 (hr) 2015-09-11
JP2014012001A (ja) 2014-01-23
LTPA2020506I1 (lt) 2020-04-27
SI3670528T1 (sl) 2022-01-31
EA200702402A1 (ru) 2008-04-28
AU2006242476B2 (en) 2012-05-31
GEP20125594B (en) 2012-08-10
CA2607197A1 (en) 2006-11-09
US9296812B2 (en) 2016-03-29
EP2264063A1 (en) 2010-12-22
PT2325199E (pt) 2015-07-10
NO20076046L (no) 2008-01-30
EP2325200A1 (en) 2011-05-25
US11939372B2 (en) 2024-03-26
IL224967B (en) 2019-03-31
TW200716667A (en) 2007-05-01
NO20230084A1 (no) 2008-01-30
HK1108705A1 (en) 2008-05-16
MX2007013759A (es) 2008-04-29
DK2325199T3 (da) 2015-05-26
BRPI0610197A2 (pt) 2010-06-01
ZA200709480B (en) 2010-07-28
ES2537278T3 (es) 2015-06-05
IL187106A (en) 2015-10-29
US7872106B2 (en) 2011-01-18
CY2020009I2 (el) 2020-11-25
HUS2000007I1 (hu) 2020-03-30
UY38207A (es) 2020-11-30
JP5789652B2 (ja) 2015-10-07
EP2336163A1 (en) 2011-06-22
HK1151803A1 (zh) 2012-02-10
WO2006119107A9 (en) 2007-09-20
TNSN07406A1 (en) 2009-03-17
EA201400933A1 (ru) 2015-04-30
EP3985015A1 (en) 2022-04-20
EP2325199B1 (en) 2015-03-04
JP5409952B2 (ja) 2014-02-05
TW201741332A (zh) 2017-12-01
EP1891101B8 (en) 2013-06-26
CN103819558B (zh) 2016-08-24
US20240270835A1 (en) 2024-08-15
PT1891101E (pt) 2013-08-23
PL1891101T3 (pl) 2013-11-29
WO2006119107A2 (en) 2006-11-09
PT3670528T (pt) 2021-12-09
KR20080011420A (ko) 2008-02-04
LTC1891101I2 (lt) 2020-09-25
SG10201403400UA (en) 2014-10-30
TWI778444B (zh) 2022-09-21
US8637643B2 (en) 2014-01-28
IL187106A0 (en) 2008-02-09
US20110097342A1 (en) 2011-04-28
US7592429B2 (en) 2009-09-22
CN101287756A (zh) 2008-10-15
NO348331B1 (no) 2024-11-25
PH12015501848A1 (en) 2020-07-06
AR053266A1 (es) 2007-04-25
PL2325199T3 (pl) 2015-08-31
KR20140037293A (ko) 2014-03-26
US20160168241A1 (en) 2016-06-16
CY1124802T1 (el) 2022-11-25
RS52919B (sr) 2014-02-28
US10562964B2 (en) 2020-02-18
KR101653122B1 (ko) 2016-08-31
CA2607197C (en) 2016-12-13
EA021539B1 (ru) 2015-07-30
HUE057097T2 (hu) 2022-04-28
HRP20130803T1 (hr) 2013-11-08
MX358705B (es) 2018-08-31
JP2014061000A (ja) 2014-04-10
BRPI0610197B1 (pt) 2021-05-11
EA037044B1 (ru) 2021-01-29
NZ591636A (en) 2012-10-26
AU2006242431A1 (en) 2006-11-09
NO346914B1 (no) 2023-02-27
IL224968B (en) 2018-03-29
US20070110747A1 (en) 2007-05-17
TWI712613B (zh) 2020-12-11
NO345294B1 (no) 2020-11-30
US8383801B2 (en) 2013-02-26
KR101450888B1 (ko) 2014-10-16
RS62685B1 (sr) 2021-12-31
KR101624809B1 (ko) 2016-05-26
EP1891101A2 (en) 2008-02-27
CA2947080A1 (en) 2006-11-09
CY2020009I1 (el) 2020-11-25
EP2264063B1 (en) 2018-06-27
LT3670528T (lt) 2021-12-27
EP3670528B1 (en) 2021-09-08
NO2021014I1 (no) 2021-03-24
ME02247B (me) 2015-10-30
BRPI0610197B8 (pt) 2021-05-25
DK1891101T3 (da) 2013-08-26
JP2008539726A (ja) 2008-11-20
CN103435698A (zh) 2013-12-11
CN107446043A (zh) 2017-12-08
TWI888751B (zh) 2025-07-01
KR20130126752A (ko) 2013-11-20

Similar Documents

Publication Publication Date Title
ME02085B (me) Sklerostin vezujuća sredstva
JP7361086B2 (ja) スクレロスチンエピトープ
JP2008539726A5 (me)
HRP20201438T1 (hr) Metoda inhibiranja resorpcije kosti
US20100036091A1 (en) Antibody-based diagnostics and therapeutics
JP2010539190A5 (me)
CN103649118A (zh) 双特异性结合剂
TW201305198A (zh) Ｄｋｋ１抗體及使用方法
TW200902549A (en) Anti-FGF23 antibody and pharmaceutical composition comprising the same
CN104619342A (zh) 骨疾病的治疗
JP2015524386A5 (me)
EP2739311B1 (en) Method for treating bone gap defects
CN107750254B (zh) 抗Dkk-1-抗RANKL双特异性抗体化合物
HK1196251A (en) Method for treating bone gap defects
HK1196251B (en) Method for treating bone gap defects
HK1250046B (zh) 抗dkk-1-抗rankl双特异性抗体化合物
HK1149021A (en) Sclerostin epitopes
HK1194748A (en) Sclerostin and dkk-1 bispecific binding agents